ALK and plasma cell myeloma: Deregulation of the SHH signaling pathway has been implicated in lymphoma such as small lymphocytic lymphoma, plasma cell myeloma, mantle cell lymphoma, diffuse large B-cell lymphoma, chronic myelogenous leukemia, acute leukemias and anaplastic lymphoma kinase (ALK) - positive anaplastic large cell lymphoma, as well as sporadic cancers such as gastric cancer, basal cell carcinoma, medulloblastoma, pancreatic cancer, breast cancer, ovarian cancer, small-cell lung cancer, and colorectal cancer 10-14.